Pharmacokinetics of sertindole in healthy young and elderly male and female subjects

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 2, 1997, Pages 157-164

  Wong, Shekman L ^a   Cao, Guoliang ^a   Mack, Randall J ^a   Granneman, G Richard ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; SERTINDOLE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SEX DIFFERENCE;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGING; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; SEX CHARACTERISTICS;

EID: 0030881591     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90063-1     Document Type: Article

References (16)

1. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124: 168-75.
2. Martin PT, Grebb JA, Schmitz P, Sebree TB, Kashkin KB, and the M92-762 and M92-817 Sertindole Research Groups. Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patient [abstract]. Schizophr Res 1994;11:107.
3. Ramirez L, Foley S, Dawson M, Zylberman K, Mack R. The long-term safety of sertindole [abstract]. Society of Biological Psychiatry, San Diego, CA, May 14-18, 1997.
4. Zborowski J, Schmitz P, Staser J, O'Neil J, Giles K, Wallin B, et al. Efficacy and safety of sertindole in a trial of schizophrenic patient [abstract]. 148th Meeting of the American Psychiatric Association, Philadelphia, PA, May 20-25, 1994.
5. Wong SL, Linnen P, Mack R, Granneman GR. Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos [in press].
6. Sakamoto K, Nakamura Y, Aikoh S, Baba T, Perregaard J, Pedersen H, et al. Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica 1995;25:1327-43.
7. Wong SL, Menacherry S, Mulford D, Schmitz P, Locke C, Granneman GR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol [in press].
8. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
9. Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L. Should clearance be normalised to body surface or lean body mass? Br J Clin Pharmacol 1981;11:523-6.
10. Cole IWL, Grizzle IE. Applications of multivariate analysis of variance to repeated measures experiments. Biometrics 1966;22:810-28.
11. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1989;17:236-63.
12. Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet 1994;26:243-7.
13. Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984;9:189-202.
14. Grossman MI, Kirsner JB, Gillespie IA. Basal and histalog stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 1963;45:14-26.
15. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-39.
16. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.